Pacer Advisors
CLDX icon

Pacer Advisors’s Celldex Therapeutics CLDX Stock Holding History

Pacer Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35K Buy
+938
New +$30.3K ﹤0.01% 2124
2024
Q3 		– Sell
-680
Closed -$25.2K – 2589
2024
Q2 		$25.2K Sell
680
-210
-24% -$7.92K ﹤0.01% 3384
2024
Q1 		$37.4K Buy
+890
New +$36.5K ﹤0.01% 3289
2021
Q2 		– Sell
-2,828
Closed -$58K – 1439
2021
Q1 		$58K Sell
2,828
-828
-23% -$19K ﹤0.01% 1424
2020
Q4 		$64K Buy
+3,656
New +$65.8K ﹤0.01% 1398

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pacer Advisors's CLDX Position: Q2 2026 in Review

Pacer Advisors opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 938 shares worth $35K. The stake represents ﹤0.01% of the portfolio and ranks #2124 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in CLDX as recently as Q2 2024.

Pacer Advisors first reported a position in CLDX in Q4 2020 and has held it in 5 quarters since. The position peaked at $64K in Q4 2020. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Pacer Advisors held 938 shares of Celldex Therapeutics worth $35K as of Q2 2026.
  • Celldex Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2124 holding.
  • Pacer Advisors first reported a position in Celldex Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • Pacer Advisors's Celldex Therapeutics position peaked at $64K in Q4 2020.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.